Glatiramer acetate
FDA approved · RxImmunomodulatory synthetic polypeptide
Also known as: Copaxone, Glatopa
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 127 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Glatiramer acetate is a synthetic mixture of polypeptides made from four amino acids (glutamic acid, lysine, alanine, and tyrosine), sold under names including Copaxone and Glatopa. It is thought to act by shifting immune responses away from attacking myelin, the protective coating of nerves, partly by promoting regulatory and anti-inflammatory T cell activity. Its exact mechanism is not fully understood.
What the evidence shows
Glatiramer acetate is FDA-approved for relapsing forms of multiple sclerosis, supported by a large body of human research including 119 registered trials reaching Phase 4 and over 2,300 published papers. Evidence for uses outside multiple sclerosis is much more limited.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Diagnosis and Treatment of Multiple Sclerosis: A Review.
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Oral tolerance.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.